Institute of Immunology, PLA, Third Military Medical University, 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, People's Republic of China.
Dig Dis Sci. 2011 Aug;56(8):2215-20. doi: 10.1007/s10620-011-1587-0. Epub 2011 Feb 12.
Thymic stromal lymphopoietin is a novel IL-7-like cytokine that exerts immunomodulatory effects and is constitutively expressed by intestinal epithelial cells in response to commensal bacteria colonization. Thymic stromal lymphopoietin can directly or indirectly promote Th2 and Treg responses, and is believed to inhibit Th1 and Th17 responses and limit the expression of proinflammatory cytokines such as IL-17 and IFN-γ. In response to infection by enteric pathogens, intestinal epithelial cells upregulate thymic stromal lymphopoietin expression in order to generate balance between inflammation and immune clearance. Recently, however, aberrant expression of thymic stromal lymphopoietin has been associated with inflammatory bowel disease. Thus, we sought to examine the relationship between the TLSP-TSLPR pathway and inflammation in hopes of contributing to the search for a novel therapeutic target to treat a variety of inflammatory diseases, including inflammatory bowel disease.
胸腺基质淋巴细胞生成素是一种新型的 IL-7 样细胞因子，具有免疫调节作用，并在应对共生菌定植时由肠道上皮细胞组成性表达。胸腺基质淋巴细胞生成素可以直接或间接促进 Th2 和 Treg 反应，被认为抑制 Th1 和 Th17 反应，并限制促炎细胞因子（如 IL-17 和 IFN-γ）的表达。在受到肠道病原体感染时，肠道上皮细胞上调胸腺基质淋巴细胞生成素的表达，以在炎症和免疫清除之间产生平衡。然而，最近胸腺基质淋巴细胞生成素的异常表达与炎症性肠病有关。因此，我们试图研究 TLSP-TSLPR 通路与炎症之间的关系，以期为寻找治疗各种炎症性疾病（包括炎症性肠病）的新型治疗靶点做出贡献。
